Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM ) announced today that data presented this
week demonstrated that in Pfizer Inc's (NYSE: PFE ) phase III trial of
Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Approval Dependent on Outcomes of New Analyses or Confirmatory Trial
Conference Call to Discuss Strategy Scheduled for Tuesday March 18, 2008
BERKELEY HEIGHTS, N.J., March 17 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) announced that the Food and Drug
New Phase IV Clinical Study Indicates LidoSite Provides
Rheumatology Patients Superior Pain Relief
FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings
(Nevada), Inc. (OTCBB: VYHN), today announced results from a new
phase IV "Open Label" clinical study demonstrating that LidoSite,
the first FDA approved active patch for dermal analgesia, provided
better pain relief to more than 73 ...
ACC Presentation Indicates Interleukin-1 Gene Variants Determine
Increased Risk for Coronary Artery Disease from Oxidized
WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Interleukin
Genetics, Inc. (AMEX:ILI) and collaborators at the University of
California San Diego today reported at the American College of
Cardiology annual meeting that associations between coronary artery
disease (CAD) and both oxidized phospholipi...
Positive Statistical Analysis from Synthetic Blood's Oxycyte
Traumatic Brain Injury Trial Indicates Achievement of Primary
COSTA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - Synthetic Blood
International, Inc. (OTCBB:SYBD) today announced positive data from
a statistical analysis of its Phase IIa study with Oxycyte(TM) in
patients with traumatic brain injury. In line with preliminary
study results announced in Decembe...
AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin
Cells Have the Ability to Recognize, Transport and Utilize
L-ergothioneine (EGT) As A Protector Against Oxidative Damage
Clinical Poster Presented at Society for Investigative Dermatology
FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermatics
recently announced new comparative clinical data that indicates
that OCTN-1 skin cells have the ability to recognize, transport and
utilize L-ergothioneine (EGT) as a prote...
Research Indicates Geron's Human Embryonic Stem Cell-Based
Therapeutic for Spinal Cord Injury Evades Direct Attack by the
Human Immune System
MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Geron
Corporation (Nasdaq:GERN) today announced the presentation of
research studies indicating that GRNOPC1, the company's human
embryonic stem cell (hESC)-based therapeutic for the treatment of
spinal cord injury, evades a direct attack by the h...
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - Repros
Therapeutics Inc. (NasdaqGM:RPRX) today announced that an article
has been published in the July 1, 2007 issue of Oncology Reports
indicating a potential for a new approach to the treatment of
breast cancer using Proellex. The article revi...
Study Shows Brain Fitness can Save Medicare Billions
...ata indicated that those patients had lower predicted healthcare costs by about $143 less per year (or $128 on an unadjusted basis.)
"This data indicates
that we can have better health outcomes at significantly lower costs," said Henry Mahncke, PhD, vice president of Research at Posit Science. "It also...
Scientists Discover Origin of Malaria
... originated, but represent potentially powerful tools for developing vaccines and treatments against this deadly scourge. Discovery of these parasites indicates
that there is a much broader range of close relatives to the human parasite than were previously recognized, some of which might provide key insights ...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
...ng a complete written protocol to first patient in 46 days, with FDA clearance of the IND on day 44. Research elsewhere cited in the Zero Delay paper indicates
enrollment of the first patient after having a final protocol typically takes 3-6 months.
Administrative tasks accomplished before the FDA's ru...
Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
...tility of screening with an HPV test rather than a Pap test," explains Dr. Massad. "The research shared and discussed during this section of the Forum indicates
that if administered prior to first exposure, the vaccine can prevent up to 70 percent of cervical cancers. But many women are being vaccinated after...
Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
...h Annual Meeting in Boca Raton, FL, Antonio DeSimone, M.D., a neuroradiologist at the "San Giovanni Bosco" Hospital in Naples, Italy, shared data that indicates
that while patients whose aneurysms were successfully treated with coiling may still need psychological support because of this life-changing event, ...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
...ogy) in 2002, and has
become a global standard measurement of inflammation and destruction
in those joints. For these scores a lower value indicates
** Synovitis: inflammation of the synovial membrane lining joints
Osteitis: inflammation of the bone
July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
...thLetter.MayoClinic.com or call toll-free for subscription information, 800-333-9037, extension 9771.
An ever-expanding body of research indicates
that a positive outlook may improve health, decrease the risk of depression and increase longevity. The July issue of Mayo Clinic Health Letter high...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
...Yondelis(R); ET-743), which is a natural marine product approved in Europe. Unlike other chemotherapy agents, including trabectedin, the NCI research indicates
that the tumor cell DNA damaging effects of brostallicin are enhanced by high tumor glutathione levels, a hallmark of drug-resistant tumors. Brostall...
First Potential Lupus-Specific Treatment in Sight
...ith lupus and their loved ones, this is an historic day! With no new drugs for more than 50 years, since the Eisenhower Administration, the news today indicates
that it is possible to develop new, safe, and effective therapies for lupus. We are greatly encouraged by the positive top-line data which shows that ...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
...ine of at least 4 points on the SELENA SLEDAI disease activity scale (which indicates
a clinically important reduction in SLE disease activity); (2) no worsening...ts or more from baseline); and (3) no new BILAG A organ domain score (which indicates
a severe flare of lupus disease activity) and no more than one new BILAG B ...
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
...ective compounds regulate a number of genes differently than estradiol, a hormone therapy commonly used to treat women's health issues. This discovery indicates
that ERb agonists might be safer than current estrogens used in hormone therapy. The study also demonstrates the cell type selectivity of Menerba (MF1...
USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
... eliminates the side effect of capillary leak syndrome while retaining the cytokine and therapeutic activity of IL-2. His extensive pre-clinical data indicates
that this IL-2 analog will allow more clinically effective doses to be administered, resulting in significantly improved disease control with fewer co...
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
... pre-cancers associated with the five most common cancer-causing virus types. This is really good news for primary prevention of cervical cancer as it indicates
the vaccine could offer women additional protection against cervical cancer beyond what had at first been anticipated."
The study showed that in...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
...ents with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment.
that Lantus does not have mitogenic effects different from the human NPH insulin within the eye.
"This 5-year study is the longest randomized ...
School of Dentistry Studies Link Between Oral Health and Memory
...'t think of this as due to a memory problem. The patient may not be flossing or brushing properly as we have instructed they should. But this research indicates
that the problem may be due to memory loss as opposed to noncompliance."
This news release was issued on behalf of Newswise(TM). For more inform...
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
...iver enzyme increases and fully reversible central nervous system events.
"The observation of high response rate and durable objective responses indicates
the potential that blinatumomab and BiTE antibodies, in general, may have in fighting cancer," said Micromet's Senior Vice President and Chief Medical...
Boehringer Ingelheim Unveils Diabetes Pipeline
...gar control with commonly used diabetes medications like metformin. The significant reduction in HbA1c levels seen in this trial is encouraging as it indicates
linagliptin may have a potential role in the management of this prevalent disease," said Dr. Thor Voigt, senior vice president, Medicine and Drug Regu...
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
...(7 months vs. 3.5 months, p=0.03, HR=0.279; a hazard ratio of less than one indicates
a decreased risk of disease progression and a p-value of less than 0.05 indicates
An analysis was also reported that evaluate...
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
...ted them to an independent center for blinded review. This review is ongoing, and to date the scans from 93 patients have been evaluated. The review indicates
75 percent of these patients with primary and metastatic brain tumors appear to have stable disease after six months of treatment with XERECEPT(R), wi...
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
... CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration ("FDA") for the treatment of cocaine addiction. This indicates
that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective trea...
MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
...alternative for patients with MR who are too high risk for surgery and also indicates
the therapy potentially reduces healthcare costs by decreasing re-hospitali...d worldwide, these findings add to the evidence from the US and Europe that indicates
the MitraClip therapy may offer a minimally invasive alternative to reduce ...
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
... Analysis indicates
that one life is now saved for every six patients who receive an ICD
NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporatio...
CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
...up to six times more likely to experience a fracture
WOONSOCKET, R.I., May 11 /PRNewswire/ -- Data released today by CVS Caremark (NYSE: CVS ) indicates
that 87 percent of women 18 years and older with osteoporosis, who were taking a drug therapy to treat the disease, did not experience a fracture duri...
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
...ivir and placebo treatment groups.
"The efficacy of intravenous peramivir demonstrated in a prior study conducted by Shionogi & Company Ltd. indicates
its potential as a treatment for acute uncomplicated influenza," commented Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "Based on the ...
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
...l Investigative Ophthalmology and Visual Science.
Work from this study indicates
that intravitreally administered Palomid 529 slows photoreceptor cell death...bservation coupled with efficacy data described here and in earlier studies indicates
that Palomid 529 may be administered infrequently, possibly as little as on...
New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
...pon viral challenge after subjects took Sustenex for a period of 30 days. An initial, increased production of TNF-alpha in response to viral exposure indicates
a heightened immunological effect to protect against infection. Bacillus coagulans GBI-30, PTA-6086 is marketed under the trade name Ganeden BC30 ...
Chronic Ankle Pain May Be More Than Just a Sprain
... New information indicates
tendon injuries may be the culprit
ROSEMONT, Ill., May 1 /PRNewswire-USNewswire/ -- Ankle sprains are a common injury after a fall, sudde...
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
...uamous NSCLC are not standardized, are difficult to reproduce and can have low accuracy. miRview(TM) squamous produces a single objective measure that indicates
whether a sample is squamous or non-squamous NSCLC.
About miRview(TM) meso
miRview(TM) meso leverages microRNA's high-specificity biomark...
AACR Data Highlights InNexus Preclinical Antibody Candidate
... Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver.
"Preclinical data on DXL625 indicates
the strong promise of this candidate as a prospective treatment for NHL and Chronic Lymphatic Leukemia (CLL), and we anticipate starting clinical tria...
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
...y study ever conducted," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe that the high interest in this study indicates
a substantial need for new therapies for the treatment of postmenopausal vaginal atrophy."
The randomized, double-blind study has enrolled over ...
Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
...e even more interesting when one looks at disease-specific survival, where the mean for the response-positive group has increased to 37.3 months. This indicates
that response of treated lesions may be a good predictor of long-term outcome."
Professor Thompson added, "The interim Phase 2 results are also v...
DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
...ies, fistula patients have the fewest complications, such as infection or clotting, in comparison to any other access choices.
The abstract also indicates
35 percent of all EMPOWER educated patients chose a home modality, reflecting a stronger sense of patient independence and desire to be actively invol...